Tell us about yourself. I’m French, originally from St-Etienne area, near Lyon known for its gastronomy.
Tell us about yourself.
On the personal side, I love the mountains: climbing, hiking, camping, skiing. On the professional side, I’m a scientist by training – I originally came to Switzerland to study chemistry but left the field after my PhD. The scientific mindset has stuck with me though.
Tell us about yourself. I could share about my technical background and the different European cities that I have been living in, but let me take a different angle and share a personal story.
Tell us more about your current role at Zühlke. What does your day-to-day look like?
As a Head of Market Unit Health, I am responsible for all activities related to the Health market in Switzerland.
Tell us more about Dao Tun, why did you decide to found it and what does the name mean?
Dao Tun is a Swiss advisory consulting company, based in the Basel region, founded in 2019 and specialised in cross-border cooperation between Europe and China, primarily in the Healthcare and Life Science industry.
Tell us a little bit about yourself.
I have a financial background but I have always considered myself a business leader first. As Warren Buffett said, Finance is the language of business so I learned finance before trying to learn the industries I worked in.
Tell us more about yourself.
Currently I am serving as CTO for Nordic Nanovector before I also was the CEO for Nordic.
Tell us more about your current role at Novartis.
I’m the Global Head of IP – Platforms which means I am an IP strategist who is a trusted advisor and thought partner to the business, focusing on innovations like engineered cell therapy and gene therapy, that can be applied across multiple disease areas.
Dr Chui Fung CHONG is Senior Medical Leader in Clinical Development /Medical Affairs in pharmaceutical and medtech industries across different continents, striving to advance novel therapies to positively impact patients’ lives, with track records of leading clinical development programs on large and small molecules, as well as cell therapy in the fields of gastroenterology,
Dr. Leslie Anne Fendt currently works at Roche leading the development and commercialisation of one of Roche’s first Software-As-Medical-Device (SaMD) products, while simultaneously contributing to building out Roche’s overall digital health infrastructure, operating model, and strategy. Previously at Roche she was leading the global commercialisation of a novel immunology treatment and operationalise the product launch across 100+ affiliates. Before that, Leslie held a series of roles in sales, marketing, strategy, insights, and launch excellence both at global and affiliate level.